WILMINGTON, N.C., Aug. 7 /PRNewswire-FirstCall/ -- PPD, Inc. today launched PPD GlobalView EventNet(TM), a customizable global event management and adjudication system for expeditious review of safety and endpoint-driven data from large-scale clinical trials or registries.
Built on PPD’s proprietary electronic data capture (EDC) technology for conducting global registries and trials, the global event management and adjudication system provides access to safety events contained within clinical and/or safety databases. The secure Internet, network-based system accelerates review of data, particularly when studies with multiple sources of information on individual patients require review by a board of independent physicians. Features of the technology include online tracking of safety events, status reporting for activities and e-mail alerts to prompt and encourage timely review.
Providing access to near real-time data and source documents, PPD GlobalView EventNet enables adjudication board members to review the information at their own convenience in any location globally. Through an online interface, board members can request follow-up information or confirm adjudicated events. The system electronically compares the results of each board member’s decision and appropriately documents decisions according to established guidelines.
“PPD GlobalView EventNet can be customized to work with clients’ data management systems and can accommodate multiple event adjudication boards within the same study,” said Susan Atkinson, vice president of biostatistics and data management for PPD. “When coupled with PPD’s EDC and pharmacovigilance expertise, the technology enables us to streamline and expedite this critical component of the drug or device development process for our clients.”
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 27 countries and more than 8,700 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the value of this technology, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: rapid technological advances that make our products and services less competitive; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries; dependence on collaborative relationships; risks associated with acquisitions and investments; loss of large contracts; competition within the outsourcing industry; continued success in sales growth; the ability to attract and retain key personnel; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
Contacts for PPD Media Nancy Zeleniak +919 462 4088 nancy.zeleniak@rtp.ppdi.com Analysts/Investors Steve Smith +910 772 7585 stephen.smith@wilm.ppdi.com
PPD, Inc.
CONTACT: Media, Nancy Zeleniak, +1-919-462-4088, ornancy.zeleniak@rtp.ppdi.com, or Analysts-Investors, Steve Smith,+1-910-772-7585, or stephen.smith@wilm.ppdi.com, both of PPD, Inc.
Web site: http://www.ppdi.com/
